Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial

Favorable Follow-up Findings Include Stable Disease and a 13% Decrease in Tumor Size Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable six-month follow-up results from the first